is a biopharmaceutical company focused on the development of novel treatments for B-cell malignancies and autoimmune diseases.
Click for full image >>
12.3.18
TG Therapeutics Announces Follow-Up Data from the Triple Combo of U2 plus Pembrolizumab in Patients with Rel/Ref CLL and Richter's Transformation at the 60th Annual ASH Meeting
12.4.18
TG Therapeutics Announces Follow-Up Data from the Triple Combination of U2 plus Bendamustine in Patients with DLBCL and FL at the 60th Annual ASH Meeting